Highlights

  • Immuron (ASX:IMC) recorded record global Travelan sales of A$7.7 million in FY26, up 6 per cent on the prior year.
  • Fourth-quarter Canadian Travelan sales increased 427 per cent year-on-year, supported by refreshed packaging and Marketing activity.
  • Australia generated A$5.8 million in FY26 sales, up 10 per cent, remaining the company's largest market.
  • IMM-529 received US FDA investigational new drug approval in November 2025 and is being progressed toward Phase 2 development.

Immuron (ASX:IMC) reported its strongest-ever annual Travelan sales in FY26, with the traveller's diarrhoea supplement generating A$7.7 million in global revenue. The headline figure came alongside a significant quarterly rebound in Canada, where sales increased 427 per cent year-on-year, although the broader Business continues to rely mainly on Australia and the United States. Alongside the consumer health business, Immuron is also progressing its IMM-529 clinical program targeting recurrent Clostridioides difficile infection, creating a second potential growth pathway.

Latest Development

In its FY26 sales update released on 16 July 2026, Immuron reported global Travelan sales of A$7.7 million, representing a 6 per cent increase on the prior year and the fourth consecutive quarter of year-on-year growth. Fourth-quarter sales reached A$2.0 million, up 2 per cent, while second-half sales totalled A$3.5 million, up 7 per cent.

Canada was the standout quarterly performer, with fourth-quarter sales increasing 427 per cent compared with the prior corresponding period and second-half sales rising more than 1,000 per cent. The company attributed part of the improvement to updated Travelan packaging and marketing activity introduced during the quarter.

What the Numbers Show

The geographic mix provides important context. Canada contributed approximately A$0.2 million in FY26 sales, which was down 55 per cent on FY25 despite the strong fourth-quarter rebound. The larger contribution came from Australia, which generated A$5.8 million for the year, up 10 per cent, including A$1.6 million in the fourth quarter.

The United States contributed A$1.8 million during FY26, up 7 per cent in Australian-dollar terms and 13 per cent in US-dollar terms. Fourth-quarter US sales declined 4 per cent on a reported basis but increased 6 per cent in local currency.

Australia and the United States together represent almost all of Immuron's current Travelan Revenue base, making performance in these markets more important than the Canadian percentage growth rate alone.

Why It Matters

Immuron differs from many early-stage biotechnology companies because it has an existing commercial product generating revenue through consumer channels. The company has spent years developing Travelan as a preventative treatment for traveller's diarrhoea, while also building a pipeline of potential therapeutic applications.

The FY26 sales result provides evidence of continued Demand for Travelan, although revenue growth remains moderate. The company reported a half-year EBITDX loss excluding Research and Development of A$1.1 million, while receiving a A$1.1 million research and development tax incentive in February 2026. The business also reported cash of A$10.0 million at 31 December 2025, providing funding support for further commercial and clinical activities.

Growth Catalysts

The immediate consumer catalyst is whether the refreshed Travelan packaging and Marketing Strategy can support continued sales growth, particularly in the larger US market. Continued international travel activity may also support demand for traveller health products.

Beyond Travelan, IMM-529 represents a potential clinical growth opportunity. The candidate targets recurrent Clostridioides difficile infection and received US FDA investigational new drug approval in November 2025. Immuron has described the program as ready for Phase 2 development, supported by preclinical data from prevention and relapse models.

The company is also expanding its consumer portfolio through ProIBS, launched into the Australian and New Zealand markets. Progress across clinical development, partnerships and commercial distribution will determine the longer-term growth profile.

Risks Investors Should Watch

The main risk is that Travelan growth remains modest despite the strong quarterly Canadian comparison. The Canadian result was generated from a low base, and the company remains dependent on Australia and the United States for most revenue.

Clinical development also introduces uncertainty. Advancing IMM-529 into Phase 2 will require additional funding, and estimated future market opportunities depend on successful trials, regulatory approval and commercial adoption. The company remains loss-making, and future Capital requirements could result in Shareholder dilution.

Currency movements, limited share Liquidity and reliance on a small number of products remain additional considerations for investors assessing the company's outlook.

What Happens Next

The next key focus will be whether the Travelan marketing refresh produces sustained sales growth through upcoming quarters, particularly in the US market. Investors will also monitor progress on the IMM-529 Phase 2 program, including potential trial updates and any Partnership discussions.

The full-year financial results will provide further detail on profitability, cash position and operating expenses following the sales update. Any commercial agreements related to the clinical pipeline would also represent an important development for the company.

Conclusion

Immuron (ASX:IMC) enters the next phase of development with record FY26 Travelan sales, improving US market performance and a clinical program that provides additional long-term potential. The Canadian sales rebound attracted attention, but the core business remains centred on Australia and the United States. Travelan revenue growth, cost management and progress with IMM-529 will determine whether the company can translate its commercial foundation and clinical Assets into a broader growth opportunity.